Use of dual recombinant vaccinia virus vectors to assay viral glycoprotein-mediated fusion with transfection-resistant primary cell targets.
Fusion mediated by the human immunodeficiency virus type-1 (HIV-1) envelope (Env) glycoprotein and the cellular CD4/chemokine receptor complex is the first step in entry and is often analyzed in cell-cell fusion assays that require Env expression by recombinant vaccinia viruses and/or target cell transfection. Primary lymphocytes and macrophages are the principal targets for HIV-1 in vivo, but are poor substrates for transfection, and constructing recombinant vaccinia viruses expressing every novel or mutant env gene is laborious. This chapter describes a fusion assay using two recombinant vaccinia viruses that express distinct RNA polymerases suitable for transfection-resistant targets, such as primary human lymphocytes and macrophages. It also uses env genes contained in plasmid vectors, eliminating the need to construct recombinant vaccinia viruses to analyze each construct. Effector 293T cells are cotransfected with SP6-driven reporter gene and T7-driven env plasmids, then infected with recombinant vaccinia virus expressing T7 polymerase. Primary lymphocyte or macrophage targets are infected with recombinant vaccinia virus expressing SP6 polymerase. Fusion mediated by effector cell Env and endogenous CD4/coreceptors in target lymphocytes or macrophages enables SP6 polymerase-mediated reporter gene transactivation. This approach provides an efficient tool to study fusion mediated by multiple-cloned primary isolate or mutant HIV-1 env genes with the primary target cell types relevant to infection in vivo.